The Role of Lysophospholipid Metabolites LPC and LPA in the Pathogenesis of Chronic Obstructive Pulmonary Disease

Overview

Journal Metabolites

Publisher MDPI

Date 2024 Jun 26

PMID 38921452

Authors

Qiqiang Zhou

Yahong Chen

Ying Liang

Yongchang Sun

Affiliations

Soon will be listed here.

Abstract

Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by persistent respiratory symptoms and airflow limitation. While there are some available treatment options, the effectiveness of treatment varies depending on individual differences and the phenotypes of the disease. Therefore, exploring or identifying potential therapeutic targets for COPD is urgently needed. In recent years, there has been growing evidence showing that lysophospholipids, namely lysophosphatidylcholine (LPC) and lysophosphatidic acid (LPA), can play a significant role in the pathogenesis of COPD. Exploring the metabolism of lysophospholipids holds promise for understanding the underlying mechanism of COPD development and developing novel strategies for COPD treatment. This review primarily concentrates on the involvement and signaling pathways of LPC and LPA in the development and progression of COPD. Furthermore, we reviewed their associations with clinical manifestations, phenotypes, and prognosis within the COPD context and discussed the potential of the pivotal signaling molecules as viable therapeutic targets for COPD treatment.

References

Wang X, Li Y, Nanayakkara G, Shao Y, Liang B, Cole L . Lysophospholipid Receptors, as Novel Conditional Danger Receptors and Homeostatic Receptors Modulate Inflammation-Novel Paradigm and Therapeutic Potential. J Cardiovasc Transl Res. 2016; 9(4):343-59. PMC: 4992420. DOI: 10.1007/s12265-016-9700-6. View

Blom M, Tool A, Wever P, Wolbink G, Brouwer M, Calafat J . Human eosinophils express, relative to other circulating leukocytes, large amounts of secretory 14-kD phospholipase A2. Blood. 1998; 91(8):3037-43. View

Chen H, Li Z, Dong L, Wu Y, Shen H, Chen Z . Lipid metabolism in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019; 14:1009-1018. PMC: 6524761. DOI: 10.2147/COPD.S196210. View

Ackerman S, Park G, Christman J, Nyenhuis S, Berdyshev E, Natarajan V . Polyunsaturated lysophosphatidic acid as a potential asthma biomarker. Biomark Med. 2016; 10(2):123-35. PMC: 4881841. DOI: 10.2217/bmm.15.93. View

Nakata J, Kondo M, Tamaoki J, Takemiya T, Nohara M, Yamagata K . Augmentation of allergic inflammation in the airways of cyclooxygenase-2-deficient mice. Respirology. 2005; 10(2):149-56. DOI: 10.1111/j.1440-1843.2005.00687.x. View

Oikonomou N, Mouratis M, Tzouvelekis A, Kaffe E, Valavanis C, Vilaras G . Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012; 47(5):566-74. DOI: 10.1165/rcmb.2012-0004OC. View

Zhao Y, He D, Zhao J, Wang L, Leff A, Spannhake E . Lysophosphatidic acid induces interleukin-13 (IL-13) receptor alpha2 expression and inhibits IL-13 signaling in primary human bronchial epithelial cells. J Biol Chem. 2007; 282(14):10172-9. PMC: 2659592. DOI: 10.1074/jbc.M611210200. View

Rabe K, Watz H . Chronic obstructive pulmonary disease. Lancet. 2017; 389(10082):1931-1940. DOI: 10.1016/S0140-6736(17)31222-9. View

Kotarsky K, Boketoft A, Bristulf J, Nilsson N, Norberg A, Hansson S . Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther. 2006; 318(2):619-28. DOI: 10.1124/jpet.105.098848. View

10.

Sheng X, Yung Y, Chen A, Chun J . Lysophosphatidic acid signalling in development. Development. 2015; 142(8):1390-5. PMC: 4392601. DOI: 10.1242/dev.121723. View

11.

Doran A, Yurdagul Jr A, Tabas I . Efferocytosis in health and disease. Nat Rev Immunol. 2019; 20(4):254-267. PMC: 7667664. DOI: 10.1038/s41577-019-0240-6. View

12.

Morimoto K, Janssen W, Fessler M, McPhillips K, Borges V, Bowler R . Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol. 2006; 176(12):7657-65. DOI: 10.4049/jimmunol.176.12.7657. View

13.

Tan S, Ramesh T, Toh X, Nguyen L . Emerging roles of lysophospholipids in health and disease. Prog Lipid Res. 2020; 80:101068. DOI: 10.1016/j.plipres.2020.101068. View

14.

Bektas M, Payne S, Liu H, Goparaju S, Milstien S, Spiegel S . A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol. 2005; 169(5):801-11. PMC: 2171605. DOI: 10.1083/jcb.200407123. View

15.

Yang S, Chen J, Ma B, Wang J, Chen J . Role of Autophagy in Lysophosphatidylcholine-Induced Apoptosis of Mouse Ovarian Granulosa Cells. Int J Mol Sci. 2022; 23(3). PMC: 8835979. DOI: 10.3390/ijms23031479. View

16.

He D, Natarajan V, Stern R, Gorshkova I, Solway J, Spannhake E . Lysophosphatidic acid-induced transactivation of epidermal growth factor receptor regulates cyclo-oxygenase-2 expression and prostaglandin E(2) release via C/EBPbeta in human bronchial epithelial cells. Biochem J. 2008; 412(1):153-62. PMC: 2659593. DOI: 10.1042/BJ20071649. View

17.

Wang Y, Wang Y, Li G . TRPC1/TRPC3 channels mediate lysophosphatidylcholine-induced apoptosis in cultured human coronary artery smooth muscles cells. Oncotarget. 2016; 7(32):50937-50951. PMC: 5239449. DOI: 10.18632/oncotarget.10853. View

18.

Sevastou I, Kaffe E, Mouratis M, Aidinis V . Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes. Biochim Biophys Acta. 2012; 1831(1):42-60. DOI: 10.1016/j.bbalip.2012.07.019. View

19.

Zhao Y, He D, Saatian B, Watkins T, Spannhake E, Pyne N . Regulation of lysophosphatidic acid-induced epidermal growth factor receptor transactivation and interleukin-8 secretion in human bronchial epithelial cells by protein kinase Cdelta, Lyn kinase, and matrix metalloproteinases. J Biol Chem. 2006; 281(28):19501-11. PMC: 2760938. DOI: 10.1074/jbc.M511224200. View

20.

Huang L, Fu P, Patel P, Harijith A, Sun T, Zhao Y . Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice. Am J Respir Cell Mol Biol. 2013; 49(6):912-22. PMC: 3931116. DOI: 10.1165/rcmb.2013-0070OC. View